MA26607A1 - Utilisation de derives de piperidine et de pyrrolidine pour le traitement de maladies comprenant des formes de degenerescence neuronale et medicaments les contenant - Google Patents

Utilisation de derives de piperidine et de pyrrolidine pour le traitement de maladies comprenant des formes de degenerescence neuronale et medicaments les contenant

Info

Publication number: MA26607A1
Authority: MA; Morocco
Prior art keywords: piperidine; treatment; diseases including; neuronal degeneration; drugs containing
Prior art date: 1998-02-10

Application number

MA25457A

Other languages

English (en)

Inventor

Alexander Alanine

Bernd Buettelmann

Neidhart Marie-Paule Heitz

Emmanuel Pinard

Rene Wyler

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-10

Filing date

1999-02-05

Publication date

2004-12-20

1999-02-05 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2004-12-20 Publication of MA26607A1 publication Critical patent/MA26607A1/fr

Links

NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical class C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
230000004770 neurodegeneration Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Pyrrole Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

MA25457A 1998-02-10 1999-02-05 Utilisation de derives de piperidine et de pyrrolidine pour le traitement de maladies comprenant des formes de degenerescence neuronale et medicaments les contenant MA26607A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP98102246		1998-02-10

Publications (1)

Publication Number	Publication Date
MA26607A1 true MA26607A1 (fr)	2004-12-20

Family

ID=8231382

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA25457A MA26607A1 (fr)	1998-02-10	1999-02-05	Utilisation de derives de piperidine et de pyrrolidine pour le traitement de maladies comprenant des formes de degenerescence neuronale et medicaments les contenant

Country Status (28)

Country	Link
US (2)	US6015824A (fr)
EP (1)	EP0937458B1 (fr)
JP (1)	JP3142527B2 (fr)
KR (1)	KR100319249B1 (fr)
CN (1)	CN1144789C (fr)
AR (1)	AR018077A1 (fr)
AT (1)	ATE285766T1 (fr)
AU (1)	AU748335B2 (fr)
BR (1)	BR9900742A (fr)
CA (1)	CA2260698A1 (fr)
CZ (1)	CZ41099A3 (fr)
DE (1)	DE69922858T2 (fr)
DK (1)	DK0937458T3 (fr)
ES (1)	ES2245808T3 (fr)
HR (1)	HRP990042A2 (fr)
HU (1)	HUP9900275A3 (fr)
ID (1)	ID23456A (fr)
IL (2)	IL128389A0 (fr)
MA (1)	MA26607A1 (fr)
NO (1)	NO990609L (fr)
NZ (1)	NZ334081A (fr)
PE (1)	PE20000276A1 (fr)
PL (1)	PL331336A1 (fr)
PT (1)	PT937458E (fr)
SG (1)	SG74120A1 (fr)
TR (1)	TR199900286A2 (fr)
YU (1)	YU5899A (fr)
ZA (1)	ZA991038B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2793245B1 (fr) *	1999-05-05	2002-10-11	Adir	Nouveaux composes pyridiniques ou piperidiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6369078B1 (en) *	1999-08-31	2002-04-09	J. Phillip Bowen	Solenopsin derivatives and analogues as fire ant suppressants
ATE274494T1 (de) *	2000-04-20	2004-09-15	Hoffmann La Roche	Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen
MXPA03004652A (es)	2000-12-21	2003-09-05	Warner Lambert Co	Derivados de piperidina como antagonistas selectivos de subtipo de n-metil-d-aspartato.
MXPA02002749A (es)	2001-03-27	2002-10-28	Warner Lambert Co	Derivados de ciclohexilamina como antagonistas del subtipo selectivo del n-metil-d-aspartato.
US7005432B2 (en)	2002-05-16	2006-02-28	Hoffman-La Roche Inc.	Substituted imidazol-pyridazine derivatives
MX2010009649A (es) *	2008-03-27	2010-12-17	Evotecv Neurosciences Gmbh	Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda.
MX2012002366A (es)	2009-08-27	2012-03-29	Merck Sharp & Dohme	Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
US8354403B2 (en) *	2009-08-27	2013-01-15	Merck Sharp & Dohme Corp.	Pyrrolidine derived beta 3 adrenergic receptor agonists
GB201714734D0 (en)	2017-09-13	2017-10-25	Atrogi Ab	New compounds and uses
GB201903832D0 (en)	2019-03-20	2019-05-01	Atrogi Ab	New compounds and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3941796A (en) *	1970-05-21	1976-03-02	Minnesota Mining And Manufacturing Company	α-(Hydroxy and alkoxy substituted)phenyl-α-(2-piperidinyl)-methanols
US4407670A (en) *	1980-02-28	1983-10-04	National Research Development Corporation	Biocidal compounds and compositions
US4342692A (en) *	1980-10-20	1982-08-03	Usv Pharmaceutical Corporation	Pyrrolidines
ZA825227B (en) *	1981-07-22	1984-03-28	Syntex Inc	Substituted pyrrolidine cardiovascular system regulators antihypertensives
AU2370084A (en) *	1983-01-24	1984-07-26	Syntex (U.S.A.) Inc.	Pyrrolidine derivatives
IE840151L (en) *	1983-01-24	1985-02-28	Syntex Inc	£(3, 4-methylenedioxy-ó-hydroxybenzyl\| pyrrolidine¹antihypertensives
US4569941A (en) *	1983-03-21	1986-02-11	Usv Pharmaceutical Corp.	Method of using phenyl-alkylene-2-pyridyl derivatives to increase cardiac contractility in a mammal
US4548951A (en) *	1983-04-21	1985-10-22	Syntex (U.S.A.) Inc.	Hypotensive benzoxathiole pyrrolidines
US4558066A (en) *	1984-05-17	1985-12-10	Syntex (U.S.A.) Inc.	Treatment and prevention of ocular hypertension
US4632929A (en) *	1985-01-17	1986-12-30	Usv Pharmaceutical Corp.	Method of hypertensive treatment using phenyl-alkylene-2-pyridyl derivatives

1999
- 1999-01-20 US US09/234,266 patent/US6015824A/en not_active Expired - Fee Related
- 1999-02-02 DK DK99102078T patent/DK0937458T3/da active
- 1999-02-02 ES ES99102078T patent/ES2245808T3/es not_active Expired - Lifetime
- 1999-02-02 EP EP99102078A patent/EP0937458B1/fr not_active Expired - Lifetime
- 1999-02-02 PT PT99102078T patent/PT937458E/pt unknown
- 1999-02-02 DE DE69922858T patent/DE69922858T2/de not_active Expired - Fee Related
- 1999-02-02 AT AT99102078T patent/ATE285766T1/de not_active IP Right Cessation
- 1999-02-05 IL IL12838999A patent/IL128389A0/xx unknown
- 1999-02-05 MA MA25457A patent/MA26607A1/fr unknown
- 1999-02-05 CZ CZ99410A patent/CZ41099A3/cs unknown
- 1999-02-05 BR BR9900742-8A patent/BR9900742A/pt not_active IP Right Cessation
- 1999-02-05 NZ NZ334081A patent/NZ334081A/xx unknown
- 1999-02-05 CA CA002260698A patent/CA2260698A1/fr not_active Abandoned
- 1999-02-06 KR KR1019990004058A patent/KR100319249B1/ko not_active Expired - Fee Related
- 1999-02-08 HU HU9900275A patent/HUP9900275A3/hu unknown
- 1999-02-08 JP JP11029850A patent/JP3142527B2/ja not_active Expired - Fee Related
- 1999-02-08 AU AU16354/99A patent/AU748335B2/en not_active Ceased
- 1999-02-08 PE PE1999000101A patent/PE20000276A1/es not_active Application Discontinuation
- 1999-02-08 SG SG1999000363A patent/SG74120A1/en unknown
- 1999-02-08 AR ARP990100528A patent/AR018077A1/es unknown
- 1999-02-09 PL PL99331336A patent/PL331336A1/xx unknown
- 1999-02-09 NO NO990609A patent/NO990609L/no not_active Application Discontinuation
- 1999-02-09 ZA ZA9901038A patent/ZA991038B/xx unknown
- 1999-02-09 YU YU5899A patent/YU5899A/sh unknown
- 1999-02-09 ID IDP990095A patent/ID23456A/id unknown
- 1999-02-09 HR HR98102246.0A patent/HRP990042A2/hr not_active Application Discontinuation
- 1999-02-10 TR TR1999/00286A patent/TR199900286A2/xx unknown
- 1999-02-10 CN CNB991018001A patent/CN1144789C/zh not_active Expired - Fee Related
- 1999-07-28 US US09/362,932 patent/US6153624A/en not_active Expired - Fee Related
2001
- 2001-07-19 IL IL14445601A patent/IL144456A0/xx unknown

Also Published As

Publication number	Publication date
CZ41099A3 (cs)	1999-09-15
PT937458E (pt)	2005-04-29
JP3142527B2 (ja)	2001-03-07
DK0937458T3 (da)	2005-05-17
KR100319249B1 (ko)	2002-01-05
CN1232025A (zh)	1999-10-20
YU5899A (sh)	2001-07-10
US6015824A (en)	2000-01-18
ID23456A (id)	2000-04-27
AR018077A1 (es)	2001-10-31
NO990609L (no)	1999-08-11
CN1144789C (zh)	2004-04-07
ZA991038B (en)	1999-08-10
US6153624A (en)	2000-11-28
ES2245808T3 (es)	2006-01-16
JP2000063384A (ja)	2000-02-29
HU9900275D0 (en)	1999-04-28
PL331336A1 (en)	1999-08-16
SG74120A1 (en)	2000-07-18
PE20000276A1 (es)	2000-04-18
EP0937458A2 (fr)	1999-08-25
TR199900286A3 (tr)	1999-09-21
DE69922858D1 (de)	2005-02-03
AU1635499A (en)	1999-08-26
IL128389A0 (en)	2000-01-31
HRP990042A2 (en)	2000-02-29
DE69922858T2 (de)	2006-04-13
EP0937458B1 (fr)	2004-12-29
TR199900286A2 (xx)	1999-09-21
IL144456A0 (en)	2002-05-23
ATE285766T1 (de)	2005-01-15
NO990609D0 (no)	1999-02-09
HUP9900275A3 (en)	2001-08-28
KR19990072459A (ko)	1999-09-27
HUP9900275A2 (hu)	1999-12-28
AU748335B2 (en)	2002-05-30
EP0937458A3 (fr)	2001-05-23
NZ334081A (en)	2000-07-28
BR9900742A (pt)	2000-05-09
CA2260698A1 (fr)	1999-08-10

Publication	Publication Date	Title
DE69322710D1 (de)	1999-02-04	Vorrichtung zum Sammeln und Mischen von biologischen/pharmazeutischen Medien
FI990268L (fi)	1999-02-10	Ei-peptidi-NK-antagonistin käytt¦ ihosairauksien ja kutinan hoitoon tarkoitettujen lääkkeiden valmistukseen
NO994014D0 (no)	1999-08-19	Arylsulfonamider og analoger derav og deres anvendelse for behandling av neurodegenerative sykdommer
CY2007001I2 (el)	2009-11-04	Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
FI963696L (fi)	1996-11-07	Geeli ihosairauksien hoitoon ja ihon desinfiointiin
DE69631531D1 (de)	2004-03-18	Katheter zur verabreidung von arzneien
EP1117357A4 (fr)	2006-05-03	Procedes et dispositifs servant a ameliorer l'administration de composes actifs sur le plan pharmaceutique
MA26559A1 (fr)	2004-12-20	Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
DE69513672D1 (de)	2000-01-05	Verbesserte vorrichtung zur iontophoretischen verabreichung von medikamenten
MA26607A1 (fr)	2004-12-20	Utilisation de derives de piperidine et de pyrrolidine pour le traitement de maladies comprenant des formes de degenerescence neuronale et medicaments les contenant
DE69825625D1 (de)	2004-09-16	Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
DE69613386D1 (de)	2001-07-19	Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE19580261D2 (de)	1997-05-28	Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktion
ATE318604T1 (de)	2006-03-15	Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen
ZA983602B (en)	1998-11-02	Use of tetrahydropyridine derivatives for the preparation of drugs for the treatment of diseases which cause demyelination
DE3875866D1 (de)	1992-12-17	Sulfonamidolphenyl-derivate und diese enthaltende therapeutische und vorbeugend wirkende mittel gegen arrhythmie.
NO307930B1 (no)	2000-06-19	Benzo[f]kinolinoner, farmasøytisk formulering omfattende samme og anvendelse av samme for fremstilling av formulering for behandling
DE69939075D1 (de)	2008-08-21	Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
DE69838785D1 (de)	2008-01-10	Pharmazeutische mittel zur behandlung von zerebralen amyloidosis
DE69420229D1 (de)	1999-09-30	Pharmazeutische Zusammensetzung zur Behandlung von AIDS
FR2717080B1 (fr)	1996-12-13	Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
FI971527L (fi)	1997-04-11	Indolijohdannaisten käyttö erilaisten sairauksien hoitoon
MA26683A1 (fr)	2004-12-20	Derives de piperidine, procede pour leur preparation, medicaments les contenant et leur utilisation dans le traitement de troubles neurologiques et physiologiques
TR199901385T2 (xx)	1999-11-22	Piperidin t�revleri.
MA26650A1 (fr)	2004-12-20	Oxo-thia -azabicyclooctenes, preparations pharmaceutiques les contenant, et leur utilisation pour le traitement et la prophylaxie de maladies infectieuses.